# Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial

> **NCT04307329** · PHASE2 · COMPLETED · sponsor: **The Netherlands Cancer Institute** · enrollment: 12 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** Monalizumab
- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT04307329
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-23
- **Primary completion:** 2023-01-19
- **Final completion:** 2024-03-23
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04307329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04307329, "Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04307329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*